Malignant Pancreatic Neoplasm — Trials

Malignant Pancreatic Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 903
Recruiting: 504
Ph III recruiting: 46
Growth YoY: +21.9%
Industry share: 32%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.5%
Trials / 1,000 deaths: 18.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (516)

clinicaltrialsPublishedShowing 51–72 of 72 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05562297	Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer	not yet recruiting	Phase 2	50	Shanghai Zhongshan HospitalOTHER	1	Jan 22, 2025	clinicaltrials
NCT06759090	Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer	not yet recruiting	Phase 2	43	Zhejiang UniversityOTHER	1	Jan 6, 2025	clinicaltrials